交易 Lyell Immunopharma Inc - LYEL 差價合約

交易條件

• 類型該金融市場可進行差價合約交易。了解更多：差價合約: 差價合約
• 點差: 0.29
• 長倉隔夜倉息調整長倉隔夜倉息調整保證金。您的投資$1,000.00隔夜倉息來自頭寸全值的費用-0.02246 %(-$1.12)使用杠杆的交易規模（大約值）$5,000.00來自杠杆的資金 - 美元（大約值）$4,000.00前往平台: -0.02246%
• 短倉隔夜倉息調整短倉隔夜倉息調整保證金。您的投資$1,000.00隔夜倉息來自頭寸全值的費用0.00023 %($0.01)使用杠杆的交易規模（大約值）$5,000.00來自杠杆的資金 - 美元（大約值）$4,000.00前往平台: 0.00023%
• 隔夜倉息調整時間: 22:00 (UTC)
• 貨幣: USD
• 最低成交量: 1
• 保證金: 20.00%
• 證券交易所: United States of America
• 交易佣金: 0%
• 保證止損溢價保證止損 (GSL) 費用僅在 GSL 被觸發時收取。更多詳情請參閱我們網站的「服務費用」 頁面。: 1%

• 保證金。您的投資: $1,000.00
• 隔夜倉息來自頭寸全值的費用: -0.02246 %
  (-$1.12)

• 保證金。您的投資: $1,000.00
• 隔夜倉息來自頭寸全值的費用: 0.00023 %
  ($0.01)

主要統計數據

• 前收盤價: N/A
• 開倉: 15.06
• 1 年變化: 88.25%
• 日區間: 13.74 - 15.99

交易 Lyell Immunopharma Inc - LYEL

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.